首页> Haematologica> The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.

导出 OA

翻译打印收藏纠错

第一作者： Stuart W,Hicks

第一单位： ImmunoGen Inc., Waltham, MA, USA.

作者： Stuart W,Hicks ^[1] ; Chiara,Tarantelli ^[2] ; Alan,Wilhem ^[1] ; Eugenio,Gaudio ^[2] ; Min,Li ^[1] ; Alberto J,Arribas ^[2] ; Filippo,Spriano ^[2] ; Roberta,Bordone ^[3] ; Luciano,Cascione ^[4] ; Katharine C,Lai ^[1] ; Qifeng,Qiu ^[1] ; Monica,Taborelli ^[5] ; Davide,Rossi ^[6] ; Georg,Stussi ^[3] ; Emanuele,Zucca ^[3] ; Anastasios,Stathis ^[3] ; Callum M,Sloss ^[7] ; Francesco,Bertoni ^[8]

作者单位： ImmunoGen Inc., Waltham, MA, USA. ^[1] Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland. ^[2] Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. ^[3] Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.;Swiss Institute of Bioinformatics, Lausanne, Switzerland and. ^[4] Cytogenetics Laboratory, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. ^[5] Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.;Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. ^[6] ImmunoGen Inc., Waltham, MA, USA frbertoni@mac.com callum.sloss@immunogen.com. ^[7] Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland frbertoni@mac.com callum.sloss@immunogen.com. ^[8]